

2016

## Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations

V. Ljungstrom

D. Cortese

E. Young

T. Pandzic

L. Mansouri

*See next page for additional authors*

Follow this and additional works at: <https://academicworks.medicine.hofstra.edu/publications>

 Part of the [Medical Molecular Biology Commons](#)

---

### Recommended Citation

Ljungstrom V, Cortese D, Young E, Pandzic T, Mansouri L, Plevova K, Ntoufa S, Baliakas P, Chiorazzi N, Rosenquist R, . Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations. . 2016 Jan 01; 127(8):Article 2974 [ p.]. Available from: <https://academicworks.medicine.hofstra.edu/publications/2974>. Free full text article.

This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic Works. It has been accepted for inclusion in Journal Articles by an authorized administrator of Donald and Barbara Zucker School of Medicine Academic Works. For more information, please contact [academicworks@hofstra.edu](mailto:academicworks@hofstra.edu).

---

**Authors**

V. Ljungstrom, D. Cortese, E. Young, T. Pandzic, L. Mansouri, K. Plevova, S. Ntoufa, P. Baliakas, N. Chiorazzi, R. Rosenquist, and +24 additional authors



Blood. 2016 Feb 25; 127(8): 1007–1016.

PMCID: PMC4768426

Prepublished online 2015 Dec 16.

PMID: [26675346](https://pubmed.ncbi.nlm.nih.gov/26675346/)

doi: [10.1182/blood-2015-10-674572: 10.1182/blood-2015-10-674572]

## Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent *RPS15* mutations

[Viktor Ljungström](#)<sup>1,\*</sup>, [Diego Cortese](#)<sup>1,\*</sup>, [Emma Young](#)<sup>1</sup>, [Tatjana Pandzic](#)<sup>1</sup>, [Larry Mansouri](#)<sup>1</sup>, [Karla Plevova](#)<sup>2</sup>, [Stavroula Ntoufa](#)<sup>3</sup>, [Panagiotis Baliakas](#)<sup>1</sup>, [Ruth Clifford](#)<sup>4</sup>, [Lesley-Ann Sutton](#)<sup>1</sup>, [Stuart J. Blakemore](#)<sup>5</sup>, [Niki Stavroyianni](#)<sup>6</sup>, [Andreas Agathangelidis](#)<sup>7,8</sup>, [Davide Rossi](#)<sup>9</sup>, [Martin Höglund](#)<sup>10</sup>, [Jana Kotaskova](#)<sup>2</sup>, [Gunnar Juliusson](#)<sup>11</sup>, [Chrysoula Belessi](#)<sup>12</sup>, [Nicholas Chiorazzi](#)<sup>13</sup>, [Panagiotis Panagiotidis](#)<sup>14</sup>, [Anton W. Langerak](#)<sup>15</sup>, [Karin E. Smedby](#)<sup>16</sup>, [David Oscier](#)<sup>17</sup>, [Gianluca Gaidano](#)<sup>9</sup>, [Anna Schuh](#)<sup>4</sup>, [Frederic Davi](#)<sup>18</sup>, [Christiane Pott](#)<sup>19</sup>, [Jonathan C. Strefford](#)<sup>5</sup>, [Livio Trentin](#)<sup>20</sup>, [Sarka Pospisilova](#)<sup>2</sup>, [Paolo Ghia](#)<sup>7,8</sup>, [Kostas Stamatopoulos](#)<sup>1,3,6</sup>, [Tobias Sjöblom](#)<sup>1,†</sup> and [Richard Rosenquist](#)<sup>1,†</sup>

<sup>1</sup>Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden;

<sup>2</sup>Central European Institute of Technology, Masaryk University and University Hospital Brno, Brno, Czech Republic;

<sup>3</sup>Institute of Applied Biosciences, Center for Research and Technology Hellas, Thessaloniki, Greece;

<sup>4</sup>Oxford National Institutes of Health Research Biomedical Research Centre, University of Oxford, Oxford, United Kingdom;

<sup>5</sup>Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom;

<sup>6</sup>Hematology Department and Hematopoietic Cell Transplantation Unit, G. Papanicolaou Hospital, Thessaloniki, Greece;

<sup>7</sup>Università Vita-Salute San Raffaele and

<sup>8</sup>Division of Experimental Oncology and Department of Onco-Hematology, Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele Scientific Institute, Milan, Italy;

<sup>9</sup>Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy;

<sup>10</sup>Department of Medical Sciences, Section of Hematology, Uppsala University, Uppsala, Sweden;

<sup>11</sup>Department of Laboratory Medicine, Stem Cell Center, Lund University, Lund, Sweden;

<sup>12</sup>Hematology Department, General Hospital of Nikea, Piraeus, Greece;

<sup>13</sup>Karches Center for Chronic Lymphocytic Leukemia Research, The Feinstein Institute for Medical Research, Manhasset, New York;

<sup>14</sup>First Department of Propaedeutic Medicine, School of Medicine, University of Athens, Athens, Greece;

<sup>15</sup>Department of Immunology, Laboratory for Medical Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands;

<sup>16</sup>Department of Medicine Solna, Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden;

<sup>17</sup>Department of Haematology, Royal Bournemouth Hospital, Bournemouth, United Kingdom;

<sup>18</sup>Laboratory of Hematology and Université Pierre et Marie Curie, Hôpital Pitié-Salpêtrière, Paris, France;

<sup>19</sup>Second Medical Department, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; and

<sup>20</sup>Department of Medicine, Hematology and Clinical Immunology Branch, Padua University School of Medicine, Padua, Italy

✉ Corresponding author.

\* V.L. and D.C. contributed equally to this study.

† T.S. and R.R. contributed equally to this study.

Received 2015 Oct 13; Accepted 2015 Dec 13.

Copyright © 2016 by The American Society of Hematology

### Key Points

- Whole-exome sequencing of CLL patients who relapsed after FCR treatment revealed frequent mutations in *RPS15*.
- *RPS15* mutations are likely to be early clonal events and confer poor prognosis.

### Abstract

Fludarabine, cyclophosphamide, and rituximab (FCR) is first-line treatment of medically fit chronic lymphocytic leukemia (CLL) patients; however, despite good response rates, many patients eventually

relapse. Although recent high-throughput studies have identified novel recurrent genetic lesions in adverse prognostic CLL, the mechanisms leading to relapse after FCR therapy are not completely understood. To gain insight into this issue, we performed whole-exome sequencing of sequential samples from 41 CLL patients who were uniformly treated with FCR but relapsed after a median of 2 years. In addition to mutations with known adverse-prognostic impact (*TP53*, *NOTCH1*, *ATM*, *SF3B1*, *NFKBIE*, and *BIRC3*), a large proportion of cases (19.5%) harbored mutations in *RPS15*, a gene encoding a component of the 40S ribosomal subunit. Extended screening, totaling 1119 patients, supported a role for *RPS15* mutations in aggressive CLL, with one-third of *RPS15*-mutant cases also carrying *TP53* aberrations. In most cases, selection of dominant, relapse-specific subclones was observed over time. However, *RPS15* mutations were clonal before treatment and remained stable at relapse. Notably, all *RPS15* mutations represented somatic missense variants and resided within a 7 amino-acid, evolutionarily conserved region. We confirmed the recently postulated direct interaction between RPS15 and MDM2/MDMX and transient expression of mutant RPS15 revealed defective regulation of endogenous p53 compared with wild-type RPS15. In summary, we provide novel insights into the heterogeneous genetic landscape of CLL relapsing after FCR treatment and highlight a novel mechanism underlying clinical aggressiveness involving a mutated ribosomal protein, potentially representing an early genetic lesion in CLL pathobiology.

## Introduction

---

The clinical course of patients with chronic lymphocytic leukemia (CLL) is highly variable and ranges from rapid disease progression requiring early treatment to survival for decades without any need for therapy. Today, the gold standard first-line regimen in young, medically fit CLL patients is chemoimmunotherapy (ie, the combination of fludarabine, cyclophosphamide, and an anti-CD20-antibody, rituximab [FCR]).<sup>1,2</sup> Although this therapy is initially effective, achieving a 90% overall response rate, most patients will relapse, often with a more aggressive disease and in rapid need of secondary treatment, especially if relapse occurs within a short time (<2-3 years) after receiving FCR.<sup>1,2</sup>

With the advent of next-generation sequencing, new insights into the molecular landscape of CLL have been achieved.<sup>3-8</sup> In addition to the well-documented *TP53* aberrations, recurrent somatic mutations were recently discovered within genes involved in key cellular processes (eg, NOTCH signaling, RNA splicing, nuclear factor  $\kappa$ B signaling). Such mutations tend to be enriched in high-risk CLL patients and have been associated with inferior outcome and even chemo-refractory disease.<sup>4-13</sup> New technologies have also facilitated the exploration into the clonal architecture of CLL, not only at a single time point, but also throughout the disease course, by analyzing longitudinal samples.<sup>14,15</sup> From these pioneering studies, it became evident that subclonal mutations (ie, variants detected in only a fraction of the tumor population) could be present at low frequencies, even remaining undetected, at early stages of the disease; however, they can be positively selected as the disease progresses, particularly after several lines of therapy.<sup>14,15</sup> The detrimental effect of low-frequency variants in CLL was recently illustrated whereby microclones carrying *TP53* mutations could be detected at diagnosis using ultra-deep sequencing; these microclones appeared to expand over time and were found to have a clinical impact similar to clonal *TP53* mutations.<sup>16,17</sup> At present, definitive conclusions cannot be drawn regarding the dynamics of clonal evolution in relation to specific treatment regimens because relevant studies have investigated relatively small cohorts of, more importantly, heterogeneously treated patients.

To overcome these limitations, we applied whole-exome sequencing (WES) of longitudinal samples collected from 41 patients with CLL who were homogeneously treated with FCR and exhibited a good initial response but relapsed within a median of 2 years. In addition to gene mutations previously associated with poor outcome, we identified recurrent mutations in *RPS15*, a gene encoding a ribosomal protein, in almost 20% of FCR-relapsing patients. Screening in extended cohorts confirmed an increased frequency of *RPS15* mutations in adverse prognostic CLL. In addition to the established role of RPS15 in protein translation, we verified the recently reported interaction between RPS15 and MDM2/MDMX<sup>18</sup>

and showed reduced stabilization and increased p53 degradation in RPS15 mutants compared with wild-type (wt) RPS15, indicating a novel molecular mechanism involved in the pathobiology of CLL.

## Methods

---

### Patient material

Forty-one CLL patients from 7 collaborating institutions in Sweden, Greece, Italy, France, the Czech Republic, the United Kingdom, and Germany were included for mutational screening using WES. All cases were diagnosed according to the International Workshop on Chronic Lymphocytic Leukemia guidelines and displayed a typical CLL phenotype.<sup>19</sup> All patients had received FCR treatment and had either obtained a complete remission (CR; n = 32) or partial remission (n = 9); at least 4 rounds of treatment were required for patients exhibiting partial remission, whereas patients with CR were included in the study irrespective of the number of treatment cycles. Response and relapse criteria were adopted according to the International Workshop on Chronic Lymphocytic Leukemia guidelines.<sup>19</sup> Patients relapsed at a median of 2.17 years (range, 1-11 years) after the first round of treatment; the main characteristics of the analyzed cases are summarized in supplemental Table 1, available on the *Blood* Web site. Peripheral blood samples were collected before the start of FCR treatment (median, 0.1 years; range, 0-2.85 years) and after treatment relapse (median, 0.51 years; range, 0-3.46 years). Constitutional DNA from sorted T cells or buccal swabs was available for 28 patients. Our extended cohort for targeted resequencing of exon 4 in *RPS15* comprised an additional 790 CLL samples (605 adverse prognostic and 185 favorable prognostic patients) from the previously mentioned institutions and from additional institutions in Greece, The Netherlands, and the United States as well as 30 cases with Richter transformation. In a second validation cohort, samples from 329 untreated patients enrolled in the UK Leukaemia Research Fund Chronic Lymphocytic Leukaemia Trial 4 (CLL4) clinical trial were investigated.<sup>20</sup> The main clinicobiological characteristics of the analyzed cases are summarized in supplemental Tables 2 and 3. Informed consent was collected according to the Helsinki Declaration and approval was granted by local ethical review committees.

### WES and data analysis

Before WES, all CLL samples were fluorescence-activated cell-sorted or underwent negative selection to enrich the tumor cell population (>95%), with the exception of 6 samples for which viable frozen cells were not available (tumor percent within these 6 samples was >60%). High-quality genomic DNA was obtained using Qiagen extraction kits. Libraries for WES were constructed using the TruSeq Exome Enrichment Kit (Illumina) and sequenced on an Illumina HiSeq 2000. The raw sequencing reads were processed using the bcbio-nextgen framework. Reads were aligned to the Hg19 reference genome using BWA-mem, version 0.7.10,<sup>21</sup> realigned using GATK, version 3.2,<sup>22</sup> and polymerase chain reaction duplicates were marked using Sambamba, version 0.4.7. Single nucleotide variants (SNV) and indels were detected using VarScan2, version 2.3.6.<sup>23</sup> Samples with matched germline DNA were analyzed using the somatic mode and the remaining samples using the mpileup2cns mode, both with a 10% variant allele frequency cutoff. Samples with matched constitutional DNA were analyzed in all targeted regions as specified by the manufacturer. From this screening, genes mutated in  $\geq 2$  samples at relapse were screened in samples without matched normal DNA. Somatic copy-number aberrations were derived from WES data using EXCAVATOR<sup>24</sup> and the output was segmented using the DNACopy R package. A high concordance was observed between WES somatic copy-number aberrations and aberrations detected by fluorescence in situ hybridization (supplemental Table 4).

### Sanger sequencing

Bidirectional Sanger sequencing of selected variants and the hotspot region of *RPS15* (exon 4) was performed using the BigDye Terminator, v3.1, Cycle Sequencing Kit and an ABI 3730 DNA Analyzer (Life Technologies). Primers are available upon request.

### Analysis of clonal composition

SciClone<sup>25</sup> enabled clustering analysis of variant allele frequencies of both the pretreatment and relapse mutations. All somatic variants, including synonymous variants and variants in noncoding regions, with coverage  $\geq 20\times$  were included in the analysis. The algorithm excludes regions affected by copy-number gain or losses; these data were obtained from EXCAVATOR.<sup>24</sup> This analysis focuses on detecting mutation clusters and delineating their intrinsic relationship rather than assigning the exact cell fraction affected by the mutation. For analysis of mutations specific to the pretreatment or relapse sample, the position was examined in the reference-called sample to ensure sufficient read depth. Assuming that the variant allele frequency of the largest detectable cluster corresponds to the total tumor population, the tumor fraction of each cluster was calculated in relation to the largest cluster at each time point.

### Cell culture

Because of the inherent difficulties in transfecting existing CLL cell lines, a well-characterized *TP53*<sup>wt</sup> colorectal cancer cell line HCT116 (ATCC) was selected; the cell line was maintained in McCoy's 5A medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin (all from Thermo Fisher Scientific Inc) and cultured in a humidified atmosphere of 5% CO<sub>2</sub> and 37°C.

### Transient transfections

Myc-DDK tagged RPS15 (RC210640), turbo green fluorescent protein (tGFP) tagged MDM2 (RG219518), and tGFP tagged MDMX constructs (RG209620) were purchased from Origene. To generate RPS15 expression vectors with p.P131S or p.G132A mutations, site-directed mutagenesis was performed using the QuikChange II kit (Agilent Technologies) with the following primers: GGCCCCGATGGGGACCGGCC (P131S fwd), GGCCGGTCCCCCATCGGGGCC (P131S rev), GGCCCCGATGGCGGGCCGGCC (G132A fwd), and GGCCGGCCCCGCCATCGGGGCC (G132A rev). The presence of mutations was confirmed by direct Sanger sequencing. Transfection of HCT116 colorectal cancer cells was performed using lipofectamine 2000 (Thermo Fisher Scientific Inc) according to the manufacturer's instructions.

### Western blot

Cells were lysed in NP40 buffer supplemented with phosphatase/protease inhibitors (Roche); protein levels were quantified by colorimetric assay (Thermo Fisher Scientific Inc). An equal amount of total protein was run on sodium dodecyl sulfate-polyacrylamide gel electrophoresis gel (NuPAGE Novex 4% to 12% Bis-Tris Gels; Thermo Fisher Scientific Inc) and transferred to nitrocellulose membranes using iBlot (Thermo Fisher Scientific Inc). Following incubation with primary antibodies, the membranes were washed in phosphate-buffered saline and incubated with secondary horseradish peroxidase-coupled goat anti-mouse and horse anti-rabbit antibodies (#7074 Sigma, 1:10 000; #7076 Sigma, 1:5000). Immunoreactive proteins were visualized using ECL western blotting detection reagent (GE Healthcare) on the ImageQuant LAS 4000 imaging system (GE Healthcare).

### Coimmunoprecipitation

HCT116 cells were cotransfected, as described previously, using an equal amount of plasmids. For immunoprecipitation, cells were harvested 24 hours' posttransfection and 500  $\mu\text{g}$  of the total cell lysates were precleared using Protein A/G Plus Agarose beads (20423, Thermo Scientific) followed by incubation



with 2 µg of either anti-DDK (TA50011-100, Origene) or anti-tGFP (TA150041, Origene) antibody overnight at +4°C. Proteins were captured on preblocked Protein A/G Plus agarose over 3 hours and immunocomplexes were washed with 1× phosphate-buffered saline and 0.1% NP40. Bound proteins were detected by western blot using anti-DDK (dilution 1:1000) and anti-tGFP (dilution 1:1000) antibodies.

### Cycloheximide-chase assay

The stability of p53 in the presence of RPS15 was detected by blocking protein synthesis using cycloheximide. Briefly, 24 hours after transfection, HCT116 cells were treated with 100 µg/mL cycloheximide and harvested at indicated time points. Cell lysates (40 µg) were analyzed by western blot (detailed previously) using anti-p53 (DO-1, Santa Cruz Biotechnology), anti-b-actin (#A5316 Cell Signaling, dilution 1:2000), and anti-c-DDK (TA100023 Origene, dilution 1:2000) antibodies. Protein bands were quantified using Image J software (<http://imagej.nih.gov/medproxy.hofstra.edu/ij>).

### Ubiquitination assay

For p53 ubiquitination assay, 24 hours after transfection with indicated plasmids, cells were treated with 30 µM MG132 (Selleckchem, S2619) for 4 hours and lysed in NP40 lysis buffer supplemented with 10 mM *N*-Ethylmaleimide (Sigma-Aldrich). Cell lysates were processed as described previously and an equal amount of total protein was resolved on 4% to 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Immunoblotting was performed with anti-p53 (DO-1, Santa Cruz Biotechnology) and anti-DDK antibodies.

### Statistical analysis

Differences in frequencies were evaluated using descriptive statistics. Associations between categorical variables were assessed using the  $\chi^2$  test for independence. Overall survival (OS) was calculated from the date of sampling until the date of last follow-up or death. Survival curves were constructed using the Kaplan-Meier method, and the log-rank test was used to determine differences between survival proportions. For all comparisons, *P* values were 2-sided and a significance level of *P* < .05 was set. All statistical analyses were performed using Statistica Software 10.0 (Stat Soft Inc).

## Results

---

### Mutational landscape in FCR-relapsing CLL

WES of 110 samples collected from 41 CLL patients who relapsed after receiving FCR treatment reached a mean effective coverage of ~60× (supplemental Table 5). For the 28 patients with matched germline DNA, 1191 somatic variants were detected in the pretreatment samples and 1334 in the relapse samples. A total of 430 variants in the pretreatment samples and 499 in the relapse samples concerned nonsynonymous mutations, rendering an average of 15.2 (range, 3-24) and 17.6 (range, 2-32) nonsilent mutations per case, respectively (Figure 1A). When comparing the 6 classes of transition and transversion mutations in the pretreatment sample vs the relapse-specific mutations, we observed a significant increase in C•G→A•T transversions at relapse (*P* = .005, Figure 1B).

Mutational screening revealed high frequencies of mutations linked to poor outcome in both pretreated and relapse samples, including *NOTCH1*, *TP53*, *ATM*, *SF3B1*, *MGA*, and *BIRC3*; similar frequencies were detected in genes recently found to be enriched in patients with aggressive disease (ie, *NFKBIE* and *EGR2*)<sup>6-13,26-28</sup> (supplemental Table 6; a complete list of mutated genes is provided in supplemental Tables 7 and 8). Twenty-six (63.4%) of 41 patients carried mutations in at least 1 of the previously mentioned genes at pretreatment rising to 33/41 (80.5%) at relapse (Figure 1C), whereas 12 (29.2%) and 15 cases (36.6%) harbored 2 or more coexisting mutations before the start of treatment and at relapse, respectively.

Intriguingly, a high frequency of mutations was detected in *RPS15* (pretreatment 7/41 cases, 17.1%; at relapse 8/41 cases, 19.5%), which encodes the ribosomal protein S15, a component of the 40S ribosomal subunit; thus far, very few CLL cases carrying mutations within this gene have been reported.<sup>9,28</sup> All mutations found within *RPS15* were missense SNVs ( $n = 7$ ) or multiple nucleotide variants ( $n = 1$ ) and, with the exception of 1 SNV, clustered to a 7 amino-acid evolutionarily conserved region within exon 4 (Figure 2A; supplemental Figure 1). Of note, 3 *RPS15*-wt cases carried mutations within 2 other ribosomal genes (ie, *RPSA* and *RPS20*) (supplemental Table 7). All *RPS15* mutations were confirmed by Sanger sequencing and their somatic origin was verified in all cases with available matched germline DNA (supplemental Table 9). All 8 *RPS15*-mutant patients carried unmutated immunoglobulin heavy variable (IGHV) genes (U-CLL); 3 had *TP53* aberrations and another 3 had 11q deletion (Figure 1C). None of the *RPS15* mutated cases showed any indication of copy number aberrations involving the *RPS15* gene (19p13.3), based on copy number WES data.<sup>24</sup> Six of the 8 *RPS15*-mutant cases achieved CR and 5/8 relapsed within 3 years (Figure 1C). However, no difference in time to relapse (median 22 months vs 26 months,  $P = .78$ ) or OS (median 114 months vs not reached,  $P = .89$ ) was seen between *RPS15*-mutated vs wt patients.

### ***RPS15* mutations are enriched within aggressive CLL**

Prompted by our finding of *RPS15* mutations, we next performed targeted resequencing of the *RPS15* hotspot (exon 4) in an extended CLL series ( $n = 790$ ), intentionally enriched for cases displaying adverse prognostic profiles ( $n = 605$ ; supplemental Table 2), and found an additional 36 mutations in *RPS15* (36/605, 6%, Figure 2B-C). In contrast, none of the 185 more favorable prognostic, IGHV-mutated CLL patients carried *RPS15* mutations (supplemental Table 2). Enrichment of *TP53* aberrations (ie, *TP53* mutations and/or del(17p)) was identified in *RPS15*-mutant versus wt *RPS15* cases (36% vs 18%,  $P < .01$ ) and a paucity of trisomy 12 (3% vs 13%,  $P < .05$ ) and *SF3B1* mutations (6% vs 20%,  $P < .05$ ), similar to the discovery cohort.

Survival analysis ( $n = 613$ ) showed an equally poor OS of *RPS15*-mutant cases with coexisting *TP53* aberrations (noteworthy is that these cases generally carried biallelic *TP53* mutation/deletion) as cases harboring *TP53* aberrations only (Figure 2E); a nonsignificant trend ( $P = .15$ ) of worse OS for *RPS15*<sup>mut</sup>/*TP53*<sup>abn</sup> cases was observed. *RPS15*-mutant patients without concomitant *TP53* aberrations had an OS similar to other aggressive CLL subgroups (patients with del(11q), *NOTCH1*, or *SF3B1* mutations vs *RPS15*-mutated;  $P = .30$ , Figure 2E-F), whereas the 10-year survival was lower for this subgroup compared with the remaining *RPS15*<sup>wt</sup>/*TP53*<sup>wt</sup> patients (0% vs 59%,  $P = .031$ ; supplemental Figure 2A), pointing to a dismal prognosis for *RPS15*-mutated CLL. Similar results were obtained in the UK CLL4 trial cohort,<sup>29</sup> which included CLL cases requiring treatment and randomized to 1 of chlorambucil, fludarabine, or fludarabine and cyclophosphamide. Overall, 12/329 (3.6%) cases within this cohort carried *RPS15* mutations (Figure 2D), and *RPS15*<sup>mut</sup>/*TP53*<sup>wt</sup> patients displayed an OS similar to other adverse prognostic groups (supplemental Figure 2B, supplemental Table 3B). Finally, we analyzed 30 cases with Richter syndrome (RS; ie, CLL transformed into diffuse large B-cell lymphoma) and only a single case was found to carry an *RPS15* mutation (Figure 2B); this mutation was also observed in the preceding CLL phase.

### ***RPS15* mutations as potential early initiating events**

Temporal dynamics of subclonal composition were investigated for 25/28 samples with matched germline DNA using SciClone.<sup>25</sup> This analysis revealed clusters of mutations that potentially correspond to individual (sub)clones. Overall, 2 general patterns were observed; the vast majority of cases exhibited either relapse-specific mutations/clusters that had expanded to become dominant or clusters that expanded more than 20% in (median) allele frequency ( $n = 23$ ), whereas the remaining 2 cases demonstrated a more stable intraclonal composition over time (supplemental Figures 3 and 4, supplemental Table 11).



Pretreatment and relapse-specific mutations were observed in all cases, indicating a branched, rather than linear, evolution pattern:<sup>30</sup> 2 characteristic examples are shown in [Figure 3](#). Although the majority of *EGR2* and *BIRC3* mutations expanded upon relapse, *NOTCH1* and *TP53* mutations remained stable or expanded and mixed patterns were observed for *ATM* and *SF3B1* mutations ([Figure 3C-E](#); supplemental Figure 5). Notably, in all but 1 case with *RPS15* mutations, the variants were detected at high allelic frequencies at both time points (median pretreatment 47.7%, median at relapse 40.2%, range 29% to 56%), implying that *RPS15* mutations may represent early initiating events in pathogenesis of CLL. RNA sequencing data were available for 4 *RPS15*-mutated cases and revealed similar variant allele frequency as WES data (supplemental Table 12). Of the available cases from both the screening and validation cohorts with variant allele frequency data for both *RPS15* and *TP53* (n = 7), 3 showed clonal *RPS15* and subclonal *TP53* mutations (<25%), whereas the remaining cases showed both clonal *RPS15* and *TP53* mutations (supplemental Table 13). The timing of the analysis in relation to diagnosis, treatment initiation, and relapse for *RPS15* mutant cases is depicted graphically in supplemental Figure 6.

### Mutated RPS15 leads to impaired p53 stability

In addition to its role in protein translation, free RPS15 protein has been shown to stabilize p53 by interfering with the MDM2-p53-MDMX network by directly binding to MDM2 and inhibiting p53 degradation.<sup>18</sup> We thus sought to investigate the potential effect of *RPS15* mutations on p53 regulation. Because most (if not all) established CLL cell lines are Epstein-Barr virus—transformed, and 1 of the most used cell lines (MEC-1) carries a *TP53* defect, we chose to use a well-characterized *TP53*<sup>wt</sup> cell line (HCT116) for the transient expression of 2 recurrent *RPS15* mutations (p.P131S and p.G132A; [Figure 2A](#)) and wt *RPS15*. First, we performed coimmunoprecipitation and confirmed the physical interaction both between RPS15 and MDM2 and RPS15 and MDMX ([Figure 4A-B](#)). A higher binding efficiency to MDM2 was noted for RPS15<sup>P131S</sup> compared with RPS15<sup>G132A</sup> and wt. Second, we studied the impact of these 2 mutants on p53 stabilization and found that the RPS15<sup>G132A</sup> mutant consistently displayed an impaired ability to regulate endogenous p53, showing a distinct reduction in p53 stabilization over time compared with wt RPS15. The analysis for the RPS15<sup>P131S</sup> mutant disclosed a minor reduction (3 independent experiments are shown in [Figure 4C-D](#) and supplemental Figure 7). Finally, to test whether reduced p53 is a consequence of ubiquitin-mediated degradation, we performed p53 ubiquitination experiments that revealed a higher level of ubiquitination in both mutants compared with wt RPS15 ([Figure 4E](#)).

## Discussion

Previous large-scale screening efforts in CLL have mainly focused on treatment-naïve patients or included samples at various time points from mixed patient groups receiving different treatment regimens.<sup>4-7,14</sup> By applying WES to samples collected longitudinally from CLL patients relapsing after FCR therapy, we aimed to describe the genomic landscape and the temporal dynamics of genetic lesions in a homogeneously treated patient group. Our prime finding concerns mutations within *RPS15*, a gene encoding a component of the ribosomal S40 subunit, which were present in almost 20% of relapsing CLL patients. In extended analyses, we noted that *RPS15* mutations were primarily found in aggressive CLL and were clonal in the pretreatment sample in the majority of cases. Finally, our pilot functional analysis indicates that *RPS15* mutations may lead to defective p53 stability and increased degradation compared with wt RPS15, representing a potential novel mechanism in CLL pathobiology.

In line with previous sequencing studies of CLL patients treated with chemoimmunotherapy, we observed that the average frequency of somatic mutations remained largely unchanged at relapse (15.2 and 17.6 mutations per case before therapy and at relapse, respectively), indicating that FCR treatment per se is not intrinsically mutagenic.<sup>6,14</sup> Nevertheless, a significant increase in C•G→A•T transversions at relapse was noted when comparing pretreatment and relapse-specific mutations. This is in line with previous

observations in relapsing acute myeloid leukemia<sup>31</sup>; however, the mechanism responsible for this enrichment of transversions at relapse remains elusive.

In a substantial proportion of cases, mutations within genes recently suggested to impact outcome or even treatment response were identified (eg, *NOTCH1*, *TP53*, *ATM*, *SF3B1*, *MGA*, *BIRC3*, *EGR2*, *NFKBIE*),<sup>6-13,26,27</sup> and the frequency of mutations within at least 1 of these genes increased from 63.5% before treatment to 80.5% at relapse (Figure 1C), indicating significant enrichment over time at least for certain genes. In agreement with a very recent study,<sup>32</sup> we also noted that mutations within known driver genes frequently occurred simultaneously (Figure 1C), hence highlighting the need to introduce targeted next-generation sequencing within the diagnostic setting,<sup>13</sup> because single-gene analysis will not suffice for correct risk stratification and outcome prediction.

In addition to the previously mentioned genes, we detected a surprisingly high number of mutations within *RPS15* (8/41 patients, 19.5%), a gene recently found mutated at only a low frequency in CLL<sup>14,28</sup> and rarely described in other cancer types. Intriguingly, with the exception of a single mutation, all mutations detected within *RPS15* resided within a 7 amino-acid evolutionary conserved region; this “hotspot” of clustered mutations points to an oncogenic rather than tumor-suppressor role of the gene. Mutations within ribosomal genes have been identified in various syndromes or inherited conditions, mainly affecting the erythroid lineage (eg, Diamond-Blackfan anemia); however, mutations within *RPL5*, *RPL10*, and *RPL22* were recently reported in T-cell acute lymphoblastic leukemia.<sup>33,34</sup> Prompted by our findings, we screened a larger number of cases to not only obtain deeper insights into the frequency of *RPS15* in CLL, but also, for the first time, to investigate their association with clinicobiological features and their impact on disease outcome. In the adverse prognostic patient group (mainly comprising U-CLL), we found that 6% of patients carried *RPS15* mutations, of which one-third (11/36) also harbored *TP53* aberrations; on the other hand, no *RPS15* mutations were detected in the more favorable prognostic, IGHV-mutated CLL. Overall, CLL patients with *RPS15* mutations (without coexisting *TP53* aberration) had a shorter 10-year survival compared with wt CLL patients, and an OS similar to patients carrying other adverse-prognostic markers (ie, 11q deletion, *SF3B1*/*NOTCH1* mutations). Cases with concomitant *RPS15* and *TP53* aberrations tended to have a worse OS than *TP53* aberrant/*RPS15* wt cases; however, the significance of this finding, if any, has to be further studied. We next screened CLL patients included in the UK CLL4 trial<sup>29</sup> and detected 12/329 patients (3.6%) carrying *RPS15* mutations. Akin to our first validation cohort, *RPS15*<sup>mut</sup>/*TP53*<sup>wt</sup> patients had a prognosis similar to other (non-*TP53*) adverse-prognostic patient groups. Finally, we analyzed 30 cases with RS and found only 1 case carrying an *RPS15* mutation (also present in the CLL phase). Hence, although *RPS15* mutations appear to be linked to clinical aggressiveness in CLL, they do not represent a mechanism underlying the histological transformation of CLL into RS.

In addition to a role in protein translation, free RPS15 has more recently been implicated in the regulation of the MDM2-p53-MDMX-axis because it binds to MDM2 and inhibits MDM2-mediated p53 degradation.<sup>18</sup> Using a well-characterized *TP53*<sup>wt</sup> cell line, we transiently expressed RPS15 mutants, representing 2 common mutations (p.P131S and p.G132A), along with wt MDM2, and corroborated the recently reported physical interaction between RPS15 and MDM2/MDMX.<sup>18</sup> Although a higher binding efficiency was seen for the RPS15<sup>P131S</sup> mutant compared with the other mutant and wt, the relevance of this finding is currently unclear. Next, we investigated the impact of RPS15 mutants on endogenous p53 regulation and, based on 3 independent experiments, observed decreased p53 stabilization compared with wt, in particular for the RPS15<sup>G132A</sup> mutant. In parallel, an increase of ubiquitin-mediated p53 degradation was observed in both RPS15 mutants compared with wt RPS15, pointing to reduced p53 stabilization as a consequence of higher p53 degradation. Although we cannot exclude the possibility that RPS15 mutants may exert their activity via non-p53-mediated pathways (eg, ribosomal regulation or other unknown functions), these data suggest a functional impairment by mutant RPS15 in regulating p53 stability compared with the wt RPS15 protein. This argument is also supported by the extreme clustering

of *RPS15* mutations within an evolutionarily conserved region, alluding to altered binding properties to MDM2 for mutant *RPS15*. However, our observations should be considered as preliminary, in particular considering that the function of *RPS15* has yet not been fully elucidated, and further studies are warranted for a more in-depth analysis of the functional role of recurrent *RPS15* mutations.

Recent seminal studies have revealed that subclones containing driver mutation(s) may confer adverse outcome in CLL and that treatment may speed up the clonal selection and outgrowth of an evolutionarily fit subclone.<sup>14,16</sup> From these studies, genetic lesions were defined to be either clonal (ie, affecting virtually all tumor cells) or subclonal (ie, where a proportion of the tumor cells carry a particular lesion). Although variant allele frequencies compensated for copy-number alterations can be exploited to determine if a somatic mutation is clonal or subclonal, groups of mutations with similarly compensated variant allele frequencies can be assigned to clusters potentially representing clones and subclones. Following this approach, we analyzed all mutations present at both pretreatment and relapse and assigned them to separate clusters using the SciClone<sup>25</sup> clustering tool. Indeed, in most cases (23/25), relapse-specific subclones and/or clusters had expanded significantly to become the dominant clone at relapse. Contrary to this, *RPS15* mutations were detected at clonal levels before treatment in all but 1 case and remained stable at relapse. Hence, in contrast to cases carrying subclonal lesions, which are enriched over time or after treatment, our data imply that *RPS15* mutations represent early initiating events and additional subclonal genetic events, such as *TP53* aberrations, may occur as the disease progresses.

In summary, we provide novel insights into the heterogeneous genomic landscape of relapsing CLL and report recurrent mutations in a “hotspot” region of *RPS15*. Validation in a larger cohort revealed enrichment of *RPS15* mutations among cases with adverse prognosis, and in vitro characterization of 2 recurrent *RPS15* mutations indicated reduced p53 stability and increased p53 degradation. Because most *RPS15* mutations were found at clonal levels even before treatment, these aberrations may represent an early genetic event in CLL pathobiology and be linked to a more aggressive disease. Hence, we propose recurring mutations within a ribosomal protein as a novel mechanism underlying clinical aggressiveness in CLL, potentially linked to p53 deregulation. These findings have implications for the optimal management of patients with CLL, raising the possibility that *RPS15*-mutant cases should be treated with alternative regimens that act independently of the p53 pathway and that mutations might be worth screening at the time of treatment decision.

## Acknowledgments

---

This work was supported by the Swedish Cancer Society; the Swedish Research Council, Uppsala University, Uppsala University Hospital; Lion’s Cancer Research Foundation; and Selander’s Foundation, Uppsala, Sweden; research project CZ.1.05/1.1.00/02.0068 of the Czech Ministry of Education, Youth and Sports, project NT13493-4/2012 of the Internal Grant Agency of the Czech Ministry of Health, and project AZV 15-31834A of the Czech Ministry of Health; the Kay Kendall Leukemia Fund, Leukemia and Lymphoma Research [the Leukaemia Research Fund Chronic Lymphocytic Leukemia 4 trial was funded by a core grant from Leukemia and Lymphoma Research], Cancer Research UK, the Bournemouth Leukemia Fund, Wessex Medical Research; Associazione Italiana per la Ricerca sul Cancro (AIRC) investigator grant (P.G., L.T.) and Special Program Molecular Clinical Oncology (5 per mille #9965 and #10007), Milano, Italy; Ricerca Finalizzata 2010 (#2318823) (P.G.) and Progetto Giovani Ricercatori (#GR-2010-2317594), Ministero della Salute, Rome, Italy; PRIN 2010-2011 (L.T.), Ministero dell’Istruzione, dell’Università e della Ricerca, Rome, Italy; Progetto di Ateneo, Università di Padova, Italy; and H2020 “AEGLE, An analytics framework for integrated and personalized healthcare services in Europe,” by the European Commission. A.A. is a fellow of AIRC (triennial fellowship “Guglielmina Lucatello é Gino Mazzega”). Sequencing was performed by the SNP&SEQ Technology Platform, SciLifeLab at Uppsala University, a national infrastructure supported by the Swedish Research Council (Council for Research Infrastructures [VRRFI]) and the Knut and Alice Wallenberg Foundation. The

computations were performed on resources provided by Swedish National Infrastructure for Computing through Uppsala Multidisciplinary Center for Advanced Computational Science under Project b2013136. Fluorescence-activated cell sorting was performed at the BioVis imaging facility, SciLifeLab, Uppsala.

## Footnotes

---

The online version of this article contains a data supplement.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

## Authorship

---

Contribution: V.L. performed research, analyzed data, and wrote the paper. D.C., E.Y., T.P., L.M., P.B., R.C., L.-A.S., and S.J.B. performed research and analyzed data. K.P., S.N., N.S., A.A., D.R., M.H., J.K., G.J., C.B., N.C., P.P., A.W.L., K.E.S., D.O., G.G., A.S., F.D., C.P., J.C.S., L.T., S.P., and P.G. contributed samples/patient data and interpreted data. K.S., T.S., and R.R. designed the study, supervised research, and wrote the paper. All authors contributed to the preparation of the manuscript and approved the submission in its current form.

Conflict-of-interest disclosure: The authors declare no competing financial interests

Correspondence: Richard Rosenquist, Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, SE-751-85 Uppsala, Sweden; e-mail: [richard.rosenquist@igp.uu.se](mailto:richard.rosenquist@igp.uu.se)

## References

---

1. Hallek M, Fischer K, Fingerle-Rowson G, et al. International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. *Lancet*. 2010;376(9747):1164–1174. [PubMed: 20888994]
2. Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. *J Clin Oncol*. 2005;23(18):4070–4078. [PubMed: 15767647]
3. Sutton LA, Rosenquist R. Deciphering the molecular landscape in chronic lymphocytic leukemia: time frame of disease evolution. *Haematologica*. 2015;100(1):7–16. [PMCID: PMC4281307] [PubMed: 25552678]
4. Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. *Nature*. 2011;475(7354):101–105. [PMCID: PMC3322590] [PubMed: 21642962]
5. Fabbri G, Rasi S, Rossi D, et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. *J Exp Med*. 2011;208(7):1389–1401. [PMCID: PMC3135373] [PubMed: 21670202]
6. Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. *N Engl J Med*. 2011;365(26):2497–2506. [PMCID: PMC3685413] [PubMed: 22150006]
7. Quesada V, Conde L, Villamor N, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. *Nat Genet*. 2012;44(1):47–52. [PubMed: 22158541]
8. Rossi D, Fangazio M, Rasi S, et al. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. *Blood*. 2012;119(12):2854–2862. [PubMed: 22308293]

9. Messina M, Del Giudice I, Khiabani H, et al. Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness. *Blood*. 2014;123(15):2378–2388. [PMCID: PMC3983613] [PubMed: 24550227]
10. Damm F, Mylonas E, Cosson A, et al. Acquired initiating mutations in early hematopoietic cells of CLL patients. *Cancer Discov*. 2014;4(9):1088–1101. [PubMed: 24920063]
11. Mansouri L, Sutton LA, Ljungström V, et al. Functional loss of I $\kappa$ B $\epsilon$  leads to NF- $\kappa$ B deregulation in aggressive chronic lymphocytic leukemia. *J Exp Med*. 2015;212(6):833–843. [PMCID: PMC4451125] [PubMed: 25987724]
12. Baliakas P, Hadzidimitriou A, Sutton LA, et al. European Research Initiative on CLL (ERIC) Recurrent mutations refine prognosis in chronic lymphocytic leukemia. *Leukemia*. 2015;29(2):329–336. [PubMed: 24943832]
13. Sutton LA, Ljungström V, Mansouri L, et al. Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting. *Haematologica*. 2015;100(3):370–376. [PMCID: PMC4349276] [PubMed: 25480502]
14. Landau DA, Carter SL, Stojanov P, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. *Cell*. 2013;152(4):714–726. [PMCID: PMC3575604] [PubMed: 23415222]
15. Schuh A, Becq J, Humphray S, et al. Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. *Blood*. 2012;120(20):4191–4196. [PubMed: 22915640]
16. Rossi D, Khiabani H, Spina V, et al. Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. *Blood*. 2014;123(14):2139–2147. [PMCID: PMC4017291] [PubMed: 24501221]
17. Malcikova J, Stano-Kozubik K, Tichy B, et al. Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia. *Leukemia*. 2015;29(4):877–885. [PMCID: PMC4396398] [PubMed: 25287991]
18. Daftuar L, Zhu Y, Jacq X, Prives C. Ribosomal proteins RPL37, RPS15 and RPS20 regulate the Mdm2-p53-MdmX network. *PLoS One*. 2013;8(7):e68667. [PMCID: PMC3713000] [PubMed: 23874713]
19. Hallek M, Cheson BD, Catovsky D, et al. International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. *Blood*. 2008;111(12):5446–5456. [PMCID: PMC2972576] [PubMed: 18216293]
20. Catovsky D, Richards S, Matutes E, et al. UK National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group; NCRI Chronic Lymphocytic Leukaemia Working Group. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. *Lancet*. 2007;370(9583):230–239. [PubMed: 17658394]
21. Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. *Bioinformatics*. 2010;26(5):589–595. [PMCID: PMC2828108] [PubMed: 20080505]
22. DePristo MA, Banks E, Poplin R, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. *Nat Genet*. 2011;43(5):491–498. [PMCID: PMC3083463] [PubMed: 21478889]
23. Koboldt DC, Zhang Q, Larson DE, et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. *Genome Res*. 2012;22(3):568–576. [PMCID: PMC3290792]



[PubMed: 22300766]


24. Magi A, Tattini L, Cifola I, et al. EXCAVATOR: detecting copy number variants from whole-exome sequencing data. *Genome Biol.* 2013;14(10):R120. [PMCID: PMC4053953] [PubMed: 24172663]
25. Miller CA, White BS, Dees ND, et al. SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution. *PLOS Comput Biol.* 2014;10(8):e1003665. [PMCID: PMC4125065] [PubMed: 25102416]
26. Edelmann J, Holzmann K, Miller F, et al. High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations. *Blood.* 2012;120(24):4783–4794. [PubMed: 23047824]
27. De Paoli L, Cerri M, Monti S, et al. MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia. *Leuk Lymphoma.* 2013;54(5):1087–1090. [PubMed: 23039309]
28. Landau DA, Tausch E, Taylor-Weiner AN, et al. Mutations driving CLL and their evolution in progression and relapse. *Nature.* 2015;526(7574):525–530. [PMCID: PMC4815041] [PubMed: 26466571]
29. Oscier DG, Rose-Zerilli MJ, Winkelmann N, et al. The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. *Blood.* 2013;121(3):468–475. [PubMed: 23086750]
30. Aparicio S, Caldas C. The implications of clonal genome evolution for cancer medicine. *N Engl J Med.* 2013;368(9):842–851. [PubMed: 23445095]
31. Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. *Nature.* 2012;481(7382):506–510. [PMCID: PMC3267864] [PubMed: 22237025]
32. Guièze R, Robbe P, Clifford R, et al. Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL. *Blood.* 2015;126(18):2110–2117. [PubMed: 26316624]
33. De Keersmaecker K, Atak ZK, Li N, et al. Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia. *Nat Genet.* 2013;45(2):186–190. [PubMed: 23263491]
34. Rao S, Lee SY, Gutierrez A, et al. Inactivation of ribosomal protein L22 promotes transformation by induction of the stemness factor, Lin28B. *Blood.* 2012;120(18):3764–3773. [PMCID: PMC3488889] [PubMed: 22976955]

## Figures and Tables

---




Figure 1




**Somatic mutation frequencies in CLL relapsing after FCR treatment.** (A) Average number of nonsynonymous mutations in both the pretreatment and relapse samples and the number of shared mutations in the 28 samples with matched constitutional DNA. (B) Frequency of the 6 mutation classes for pretreatment and relapse-specific mutations in the 28 samples with matched constitutional DNA. Statistical significance was assessed using 796 pretreatment mutations and 425 relapse-specific mutations. (C) Recurrently mutated genes. Columns represent patients ( $n = 41$ ) and rows genes or genetic lesions. Color-coding indicates the type of mutation or genomic alteration. Case names in gray were analyzed without matched normal DNA. The majority of cases with *TP53* aberrations harbored a mutation without coexisting del(17p); this is explained by the fact that the *TP53* mutation status was not known in most cases before the start of the FCR regime in contrast to fluorescence in situ hybridization detection of del(17p), which had been performed in all cases. All *TP53* mutations were deemed damaging and have been reported previously. CNA, copy-number aberration; PR, partial relapse; UPD, uniparental disomy.

Figure 2




***RPS15* mutations in CLL.** (A) Localization of SNVs detected by either WES or with targeted resequencing of exon 4 in the extension cohorts (data for each cohort are provided in supplemental Table 10). With the exception of a single mutation in amino acid 33 (not shown in figure), all mutations clustered to the C-terminal of the *RPS15* protein. Exons are marked with dashed lines and the region covered in the targeted resequencing is color coded. (B) Frequency of *RPS15* mutations in the FCR relapse cohort ( $n = 41$ ), the extended screening cohort ( $n = 605$ ), the CLL4 trial cohort ( $n = 329$ ), in RS cases ( $n = 30$ ) and IGHV-mutated/stage A patients ( $n = 185$ ). (C-D) Concurrent mutations and genetic lesions in *RPS15*-mutated cases in the extended screening cohort and the UK CLL4 cohort. (E-F) Overall survival for subgroups carrying recurrent cytogenetic and molecular aberrations. Pairwise log-rank test:  $RPS15^{mut}$  vs  $del(13q)$ ,  $P < .001$ ;  $RPS15^{mut}$  vs  $TP53^{abn}$ ,  $P = .42$ ;  $RPS15^{mut}/TP53^{abn}$  vs  $TP53^{abn}$ ,  $P = .15$ ;  $RPS15^{mut}$  vs  $RPS15^{mut}/TP53^{abn}$ ,  $P = .12$ . Ten-year survival rate for  $RPS15^{mut}/TP53^{wt}$  was similar to  $RPS15^{mut}/TP53^{abn}$  and  $RPS15^{wt}/TP53^{abn}$  patients (0%, 0%, and 22%, respectively), but lower than the remaining  $RPS15^{wt}/TP53^{wt}$  patients (59%, see supplemental Figure 7). NA, not available.

Figure 3



**Temporal dynamics of somatic mutations.** SciClone analysis of variant allele frequencies for case S42 revealed 6 predicted subclones (A). Although cluster 1 (harboring a mutation in *RPS15*), clusters 2 and 3 (carrying a frame-shift deletion in *MGA*, a gene previously found disrupted in high-risk CLL)<sup>26,27</sup> remained stable over time; clusters 4 and 6 represent relapse-specific (sub)clones, with the latter harboring a *TP53* mutation that affects 25% of tumor cells, whereas cluster 5 was eliminated. In case S17, a single stable population was detected; however, a drastic shift in (sub)clonal populations was also observed (B); clusters 4 and 6 were successfully eliminated by treatment. This is noteworthy because the former harbored the classical 2-bp deletion of *NOTCH1* and the recurrent p.K700E SNV in *SF3B1*. On the other hand, clusters 2, 3, and 5 represent relapse-specific subclones with cluster 2, which was the dominant clone at relapse, harboring a stop-gain mutation in *NOTCH1* and an SNV in *EGR2*. Results for the remaining samples are provided in supplemental Figure 4. (A-B) The mean variant allele frequency of each cluster at both time points (top right) and the fraction of each cluster in comparison with the major cluster (cluster 1; bottom right). (C-E) Variant allele frequencies for FCR relapsing cases with *RPS15*, *EGR2*, and *NOTCH1* mutations before treatment and at relapse. \*Denote 2 unique mutations in the same case (S17).

Figure 4



**In vitro characterization of *RPS15* mutations.** (A-B)  $RPS15^{G132A}$  and  $RPS15^{P131S}$  interact with MDM2 and MDMX. Immunoblot analysis of whole-cell lysates (input) and immunoprecipitates (IP) of HCT116 cells cotransfected with 1 of the Myc-DDK-*RPS15* vectors (wt, G132A or P131S) and either tGFP-MDM2 (A) or tGFP-MDMX (B). Twenty-four hours posttransfection 500  $\mu$ g of cell lysates were subjected to immunoprecipitation using anti-tGFP antibody followed by immunoblotting with indicated antibodies. Immunoglobulin G heavy chain was used as loading control for IP fraction. (C-D) Transient expression of  $RPS15^{wt}$ ,  $RPS15^{P131S}$ , and  $RPS15^{G132A}$  in HCT116 cells revealed an impaired ability to stabilize endogenous p53, in particular for the  $RPS15^{G132A}$  mutant. Western blot images from 1 representative experiment and quantification results from 3 independent experiments are shown. Images from 2 additional experiments are presented in supplemental Figure 7. (E) Ubiquitination experiments revealed increased ubiquitin-mediated p53 degradation in both *RPS15* mutants (40.1% and 40.6% increase for  $RPS15^{P131S}$  and  $RPS15^{G132A}$ , respectively, measuring the intensity for the upper 4 bands) compared with wild-type *RPS15*.

Articles from Blood are provided here courtesy of The American Society of Hematology